Your browser doesn't support javascript.
loading
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson, Paul G; Oriol, Albert; Beksac, Meral; Liberati, Anna Marina; Galli, Monica; Schjesvold, Fredrik; Lindsay, Jindriska; Weisel, Katja; White, Darrell; Facon, Thierry; San Miguel, Jesus; Sunami, Kazutaka; O'Gorman, Peter; Sonneveld, Pieter; Robak, Pawel; Semochkin, Sergey; Schey, Steve; Yu, Xin; Doerr, Thomas; Bensmaine, Amine; Biyukov, Tsvetan; Peluso, Teresa; Zaki, Mohamed; Anderson, Kenneth; Dimopoulos, Meletios.
Afiliação
  • Richardson PG; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: paul_richardson@dfci.harvard.edu.
  • Oriol A; Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Beksac M; Ankara University, Ankara, Turkey.
  • Liberati AM; Università degli studi di Perugia, Perugia, Italy.
  • Galli M; Azienda Ospedaliera Papa Giovanni XXIII, Unità Operativa di Ematologia, Bergamo, Italy.
  • Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway; K G Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
  • Lindsay J; East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, UK.
  • Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • White D; Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
  • Facon T; University of Lille, Centre Hospitalier Universitaire Lille, Service des Maladies du Sang, Lille, France.
  • San Miguel J; Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
  • Sunami K; National Hospital Organization Okayama Medical Center, Okayama, Japan.
  • O'Gorman P; Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland; Cancer Trials Ireland, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
  • Sonneveld P; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Robak P; Medical University of Lodz, Lodz, Poland.
  • Semochkin S; Pirogov Russian National Research Medical University, Moscow, Russia.
  • Schey S; Department of Hematology, King's College London, London, UK.
  • Yu X; Celgene Corporation, Summit, NJ, USA.
  • Doerr T; Celgene Corporation, Summit, NJ, USA.
  • Bensmaine A; Celgene International, Boudry, Switzerland.
  • Biyukov T; Celgene International, Boudry, Switzerland.
  • Peluso T; Celgene International, Boudry, Switzerland.
  • Zaki M; Celgene Corporation, Summit, NJ, USA.
  • Anderson K; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Dimopoulos M; National and Kapodistrian University of Athens, Athens, Greece.
Lancet Oncol ; 20(6): 781-794, 2019 06.
Article em En | MEDLINE | ID: mdl-31097405
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia de Salvação / Resistencia a Medicamentos Antineoplásicos / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia de Salvação / Resistencia a Medicamentos Antineoplásicos / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article